Novavax CoVPN 3004 Adult and Pediatric Booster Administration Project Summary/Abstract: Novavax Adult and Pediatric booster To date, 485 adult and 29 pediatric participants have received the initial series of vaccinations, had associated follow-up visits, and participated in a blinded cross-over. We estimate 380 adult and 29 pediatric participants will be invited to receive booster dose of vaccine and participate in associated follow-up visits. Blood and other protocol-required specimens collected at theses visits will be processed, stored, and shipped per protocol. Data will be entered, and data queries will be resolved in a timely manner. Surveillance for illness visits will continue and with the advent of new variants, it is expected illness visits will increase following major holidays with a gradual reduction to follow.

Novavax CoVPN 3004 Adult and Pediatric Booster Administration Narrative: Novavax Adult and Pediatric booster While the Pfizer and Moderna mRNA-based COVID-19 vaccines have received EUA for adult participants and EUA for children 12-<18 years of age, and are widely available for public receipt, the Novavax NVX-CoV2373 vaccine offers a simpler, more well-established vaccine platform with a strong safety and efficacy profile. In addition, the vaccine is easy to manufacture and requires only refrigeration storage making it easier to store and distribute. Therefore, the evaluation of this vaccine is of great public health importance in the fight against COVID-19.